Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cambrex and Cytori form stem cell partnership
Under the terms of the agreement, Cambrex will manufacture and market products to the research community under the co-exclusive license from Cytori. In return for the license, Cytori
Under the terms of the agreement, Cambrex will manufacture and market products to the research community under the co-exclusive license from Cytori. In return for the license, Cytori
These new findings from phase III studies were presented at the American Diabetes Association (ADA) meeting in Washington, DC. The combination of Galvus, a member of the DPP-4
“Existing intranasal steroids are effective against the nasal symptoms of allergic rhinitis. However, the relief of ocular symptoms remains a key unmet need for patients,” said clinical trial
The addition of these new drugs swells Aida’s product pipeline from four to seven developmental drugs. The three drugs are either being evaluated for pre-clinical trials or in
The special protocol assessment (SPA) is a process that allows for official FDA evaluation of a phase III clinical trial and provides the trial sponsor with binding written
The fast track designation will allow Bayer and Onyx to file a new drug application (NDA) on a rolling basis as data become available. This permits the FDA
The phase II study followed 32 patients with clinically diagnosed, MRI-confirmed progressive MS for 24 months, comparing safety and efficacy between MBP8298 and placebo administered intravenously every six
Pfizer and Schwarz Pharma entered into a global license agreement in April for Pfizer to acquire exclusive worldwide rights to fesoterodine, a new drug candidate for treatment for
Under the fast track designation, the FDA will help expedite the development and review of the MyVax personalized immunotherapy biologics license application (BLA) for approval. The regulator may
“This means Bayer must make a new offer to all Schering stockholders to acquire the shares they still own because Bayer now holds more than 30% of Schering